Sometimes it becomes difficult to explain to young children about masks and social distancing. In such a situation, the need for vaccine increases. Now the company is preparing to apply for permission to use it in other places including America and Europe soon.
All the vaccines that give protection against corona virus have come and vaccination is going on fast in the whole world including India. However, till now a big one was about the health of the children and now his concern also seems to be ending soon. Pfizer Inc and BioNTech SE announced on Monday that their Kovid-19 vaccine has shown a strong effect on children aged 5 to 11 years.
Now the company is preparing to apply for permission to use it in other places including America and Europe soon. The company says that in Phase II-III clinical trials of the vaccine, immune responses were seen in children aged 5-11 years, which matches the response previously seen in people of 16-25 years. Sometimes it becomes difficult to explain to young children about masks and social distancing. In such a situation, the need for vaccine increases.
decision may be taken soon
In the trial, the safety profile of the vaccine was also found to be similar to that of older people. US health officials say that regulators can make a decision on the effectiveness and safety of the vaccine within three weeks. Earlier, data from tests conducted on 2,260 volunteers aged 12-15 years found that no cases of corona infection were found after complete vaccination. That is, the vaccine was said to be 100% effective.
There were many successes, some left
The company’s vaccine Comirnaty has been approved for use on 2268 children up to the age of 12 in many countries including the US. It was earlier allowed to be used by people over the age of 16. At the same time, children aged 5-11 years were given 2 doses of 10 micrograms of the vaccine in the trial. At present, its trial is to be done on children between 2-5 and 6 months to two years of age.
How does the Pfizer vaccine work?
The Pfizer vaccine is mRNA based in the liposomes, not the viral vector, and the mRNA has a short life and action in the host cell. The mRNA along with the liposomes will move to the host cell. It will be recognized by ribosomes in the cytoplasm instead of the nucleus. This will create a protein that is similar to the spike protein of SARS-CoV-2. It will be sent to the plasma membrane of the host cell.
higher doses needed
The immune system will see this protein and an immune response will be generated. The immune system will create a memory so that it can be dealt with later in the event of a SARS-CoV-2 infection. This sequence is fixed and the genetic material of the mRNA vaccine is unlikely to remain in the host cell for long. One problem with this type of vaccine can be that high doses have to be taken for complete protection.